Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report details a specific share repurchase transaction executed on September 22, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 707,253 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,316 pence per share; lowest price paid was 1,294 pence per share.
- Treasury Shares Held: 505,396,816 shares (representing 9.07% of total issued share capital and 9.98% of total voting rights).
- Shares in Issue: 5,065,591,414 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's issued share capital through the cancellation of 707,253 repurchased shares. Consequently, the Company's Treasury shareholding increased to 505,396,816 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,065,591,414) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share percentage (9.07% of issued capital) for voting rights analysis.
- Note that this filing does not contain operational or financial performance data for the period.